{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:21:52Z","timestamp":1789399312420,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"26","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,7]]},"DOI":"10.1093\/eurheartj\/ehu079","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T00:48:34Z","timestamp":1394498914000},"page":"1743-1751","source":"Crossref","is-referenced-by-count":25,"title":["Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial"],"prefix":"10.1093","volume":"35","author":[{"given":"Koon K.","family":"Teo","sequence":"first","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"name":"Clinica Medica e Dipartimento di Medicina Clinica, Universita Milano-Bicocca, Ospedale San Gerardo di Monza, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"},{"name":"Health Research Board Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Dagenais","sequence":"additional","affiliation":[{"name":"Quebec Heart Institute, Hospital Laval, Ste-Foy, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[{"name":"Estudios Clinicos Latinoamerica, Rosario, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Dans","sequence":"additional","affiliation":[{"name":"Section of Adult Medicine, College of Medicine, University of the Philippines, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Liu","sequence":"additional","affiliation":[{"name":"National Center for Cardiovascular Diseases, Cardiovascular Institute and FuWai Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Bosch","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Joseph","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Copland","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejung","family":"Jung","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Pogue","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster-University-Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Aliskiren Prevention of Later Life Outcomes trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,9]]},"reference":[{"key":"key\n\t\t\t\t20180608034817_EHU079C1","first-page":"231","article-title":"Geographic patterns of hypertension: a global perspective","volume-title":"Hypertension Primer","author":"Cooper","year":"200","edition":"3rd ed."},{"key":"key\n\t\t\t\t20180608034817_EHU079C2","first-page":"166","article-title":"Aging, hypertension and the heart","volume-title":"Hypertension Primer","author":"Lakatta","edition":"3rd ed."},{"key":"key\n\t\t\t\t20180608034817_EHU079C3","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on the management of hypertension","volume":"21","author":"World Health Organization\/International Society of Hypertension","year":"2003","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20180608034817_EHU079C4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20180608034817_EHU079C5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension","volume":"25","year":"2007","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20180608034817_EHU079C6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/HJH.0b013e32832aa6b5","article-title":"When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal","volume":"27","author":"Zanchetti","year":"2009","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20180608034817_EHU079C7","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t20180608034817_EHU079C8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension","volume":"31","author":"The Task Force for the management of arterial hypertension on the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","year":"2013","journal-title":". J Hypertens"},{"key":"key\n\t\t\t\t20180608034817_EHU079C9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.108.110932","article-title":"Renin inhibition by aliskiren prevents atherosclerosis progression. Comparison with irbesartan, atenolol, and amlodipine","volume":"51","author":"Nussberger","year":"2008","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t20180608034817_EHU079C10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.108.787630","article-title":"Aliskiren","volume":"118","author":"Brown","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180608034817_EHU079C11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation,"},{"key":"key\n\t\t\t\t20180608034817_EHU079C12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180608034817_EHU079C13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180608034817_EHU079C14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan","volume":"20","author":"Pool","year":"2007","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t20180608034817_EHU079C15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure. The ASTRONAUT Randomized Trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180608034817_EHU079C16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"The ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180608034817_EHU079C17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"HOPE (Heart Outcomes Prevention Evaluation) Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180608034817_EHU079C18","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/35\/26\/1743\/25024718\/ehu079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:15:27Z","timestamp":1648570527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/35\/26\/1743\/508749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,9]]},"references-count":18,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2014,3,9]]},"published-print":{"date-parts":[[2014,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehu079","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,7,7]]},"published":{"date-parts":[[2014,3,9]]}}}